GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Direc...
March 07 2017 - 5:00AM
GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the
Group”), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, today announced the
appointment of Scott Giacobello as Chief Financial Officer on 6
March 2017. Reporting to GW’s Chief Executive Officer Justin Gover,
Mr. Giacobello will be based at the Company’s U.S. headquarters in
Carlsbad, California. Related to this appointment, on 6 March 2017
Adam George, GW’s Chief Financial Officer since 2012, became
Managing Director – UK, a newly-created executive role with
broad leadership responsibilities for UK operations, also reporting
to Justin Gover.
“These important leadership appointments reflect
GW’s continuing evolution into a transatlantic commercial-stage
biopharmaceutical company. In anticipation of Epidiolex approval
and launch, and with GW now solely listed on Nasdaq, we expect to
transition from being a Foreign Private Issuer reporting under IFRS
to become a domestic registrant reporting under USGAAP and in US
dollars in future years. Scott’s significant financial and
accounting expertise will be a major asset to the organization as
we make that shift,” stated Justin Gover, GW’s Chief Executive
Officer. “In addition, with Adam having served as CFO since 2012,
his new Managing Director – UK role leverages the broad knowledge
he has of our business and provides continuity of strong senior
UK-based leadership, essential elements to our continued
success.”
Scott Giacobello brings 25 years of finance and
operational experience to GW Pharmaceuticals. He is an accomplished
executive who most recently and until its acquisition by Allergan,
Inc. in late 2016, served as Chief Financial Officer for Chase
Pharmaceuticals Corporation, a clinical stage biopharmaceutical
company focused on the development and commercialization of
improved treatments for neurodegenerative disorders. From 2008
through 2015, Mr. Giacobello held senior level finance positions at
Allergan, Inc., most recently serving as Vice President of Finance
for Global Research & Development. While at Allergan, he also
served as Vice President of Corporate Finance and Vice President of
Internal Audit & Compliance. Mr. Giacobello’s previous
experience includes financial positions at the Black & Decker
Corporation and Ernst & Young, LLP. Mr. Giacobello holds a
bachelor’s degree in business administration from the University of
Notre Dame and is a Certified Public Accountant.
As Managing Director – UK, Adam George will
be instrumental in ensuring our UK operations achieve our strategic
and operating goals, which include pipeline development,
manufacturing scale-up, and European commercialization. Mr. George
will continue as Company Secretary and will provide Mr. Giacobello
with full support through the CFO transition.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW is advancing an
orphan drug program in the field of childhood epilepsy with a focus
on Epidiolex® (cannabidiol), which is in Phase 3 clinical
development for the treatment of Dravet syndrome, Lennox-Gastaut
syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW
commercialized the world’s first plant-derived cannabinoid
prescription drug, Sativex® (nabiximols), which is approved
for the treatment of spasticity due to multiple sclerosis in 31
countries outside the United States. The Company has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for glioma,
schizophrenia and epilepsy. For further information, please visit
www.gwpharm.com.
Forward-looking statements
This news release contains forward-looking
statements that reflect GW's current expectations regarding future
events, including statements regarding financial performance, the
timing of clinical trials, the timing and outcomes of regulatory or
intellectual property decisions, the relevance of GW products
commercially available and in development, the clinical benefits of
Sativex® and Epidiolex® and the safety profile and commercial
potential of Sativex and Epidiolex. Forward-looking statements
involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of
factors, including (inter alia), the success of GW’s research
strategies, the applicability of the discoveries made therein, the
successful and timely completion of uncertainties related to the
regulatory process, and the acceptance of Sativex, Epidiolex and
other products by consumer and medical professionals. A further
list and description of risks and uncertainties associated with an
investment in GW can be found in GW’s filings with the U.S.
Securities and Exchange Commission, including the most recent Form
20-F filed on 5 December 2016. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. GW undertakes
no obligation to update or revise the information contained in this
press release, whether as a result of new information, future
events or circumstances or otherwise.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations 401 500 6570
Sam Brown Inc. Healthcare Communications
(U.S. Media Enquiries)
Mike Beyer 312 961 2502
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024